Ahsan M. Basha, MD, joined Riverside Medical Center, where he will practice at Riverside’s newest location—Riverside Medical Center Specialty Services in Watseka, Illinois. Dr. Basha specializes in Medical Oncology and Hematology. Prior to coming to Riverside Medical Center, he was a partner and practiced general medical oncology and hematology at Desert Oncology Associates, LLC in Mesa, Arizona.
   
Richard C. Frank, MD, of Norwalk Medical Group, Norwalk, Connecticut, won a 2010 American Medical Writers Association First Place Award for his book, Fighting Cancer with Knowledge & Hope, published by Yale University Press.
   
“Feasibility of New-generation Infrared Imaging Screening for Breast Cancer in Rural Communities,” by ASCO member Francisco Gutierrez-Delgado, MD, PhD, FACP, of the Centre for Study and Prevention of Cancer, Oaxaca, Mexico, and José G. Vázquez-Luna, PhD, was recently published in the US Oncological Review and US Radiology. The paper was previously selected for poster presentation at the 2009 ASCO Meeting.
   
V. Craig Jordan, OBE, PhD, DSc, FMedSci, received the 2011 St. Gallen Breast Cancer Award, conferred at the 12th St. Gallen International Breast Cancer Conference this March in St. Gallen, Switzerland, for his pioneering work in the adjuvant treatment and prevention of breast cancer. He is the Scientific Director of the Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC. The St. Gallen Breast Cancer Award is given every two years to a scientist who has made exceptional contributions to the field of breast cancer research. Accordingly, Dr. Jordan has pioneered translational research that established the scientific principles for the use of tamoxifen as a long-term breast cancer treatment and then as a preventative agent.
   
Natasha B. Leighl, MD, was chosen as the Associ­ate Editor for the ASCO Educational Book. She will support Editor-in-Chief Ramaswamy Govindan, MD, in the review of all faculty-submit­ted manuscripts. Dr. Leighl is currently an Associate Professor in the Department of Medicine at the University of Toronto. She is a past recipient of ASCO Young Investigator and Career Development Awards.
   
Olufunmilayo I. Olopade, MBBS, FACP, was appointed as a member of the National Cancer Advisory Board by U.S. President Barak Obama. Dr. Olopade is the Walter L. Palmer Distinguished Service Professor of Medicine & Human Genetics, Associate Dean for Global Health, and Director of the Center for Clinical Cancer Genet­ics at the University of Chicago. She is also a practicing clinician and Director of the University’s Cancer Risk Clinic. Dr. Olopade received a Conquer Cancer Foundation (formerly the ASCO Cancer Foundation®) Young Investigator Award in 1991 and was the 2010 recipient of the ASCO/American Cancer Society Award and Lecture.

Vote on 2011 Proposed Amendments to ASCO Bylaws
The ASCO Board of Directors and Bylaws Committee are recommending amendments to the ASCO Bylaws. A vote of ASCO members is needed to approve the amendments. Eligible ASCO members are encouraged to vote “in favor of” or “against” the set of proposed amendments through a proxy ballot on ASCO’s official website, ASCO.org. Proxy ballots must be voted between March 22 and May 18, 2011, to be counted. A copy of the Bylaws with the proposed amendments and sum­maries of the proposed changes are available at webapp.asco.org/bylaws during the proxy voting period, or look for the “click here to vote” button on the homepage of ASCO.org.

The proxy ballots will be cast by the ASCO President or his designee dur­ing the 2011 Annual Business Meeting of the members on June 6, 2011, 12:00 PM-1:00 PM, at the Hyatt McCormick Place, Regency Ballroom, in Chicago, Illinois. The main proposed substantive changes are:

• Add a new Student/Non-Oncology Resident Membership Category to attract students to oncology and ASCO; cannot hold office, vote, or be voting committee members.
• Change the names of some member­ship categories to be more descriptive.
• Remove Bylaws language detailing requirements for sponsorship of membership and abstracts to stream­line the Bylaws. Requirements can be specified in other governing docu­ments and the Board can periodically review.
• Add the Chair of the Conquer Cancer Foundation of the American Society of Clinical Oncology formerly The ASCO Cancer Foundation^®) as an ex-officio,nonvoting member of the ASCO Board to enhance communica­tion and strategic planning.
• Extend the term of the designated community oncologist on the Nomi­nating Committee from one to three years to enhance effectiveness and be on par with other Nominating Committee members. Have the mem­bers elect the designated community oncologist on the Nominating Com­mittee. The Clinical Practice Commit­tee will identify nominees, from which the Nominating Committee will select ballot candidates.
• Streamline the Bylaws by referencing only committees tied to fundamen­tal governance (Executive, Finance, Audit, Compensation, and Nominat­ing Committees). Other multiple ASCO committees will continue to be addressed in other governing documents.
• Clarify that both the Board and mem­bers must approve Bylaws amend­ments and use the quorum number (100) as the number of members needed to propose Bylaws amendments.

In Memoriam
Gamal El-Wahidy, MD
John J. Fuery
William Gordon, MD, PhD
E. Dieter Hager, MD, PhD
Kamran Hassidim, MD
Gary D. Kruh, MD, PhD
Fred Kolhouse, MD
Georges Mathé, MD
Bo Nilsson, MD, PhD
Ramesh V. Patwardhan, MD
David Prager, MD
Ernest H. Rosenbaum, MD, FACP
Arthur Sawitsky, MD
Aurelio C. Tiro, MD
John J. Whitaker, MD